Top Bank Stocks To Watch For 2018

We all know financial stocks have gone through the roof since President Trump’s win. So the question becomes: what do we do with these companies now?

There’s no one answer for every financial stock, of course.

Some are still great, undervalued buys—but there are two that have gotten grossly overvalued and should be avoided, or sold if you hold them. (Below, I’ll reveal 3 better high-yield stocks to buy instead.)

These 2 Financials Are Headed for Trouble

Bank of America Corp (BAC) is the first bank on my hit list.

A Breathtaking Rise

After spending most of 2016 in the red, BAC has soared more than 37% in three months. Nothing much has changed at the bank; it’s just riding a wave of euphoria as investors bet that Trump’s America will mean higher interest rates and fewer regulations, driving up BAC’s earnings.

Top Bank Stocks To Watch For 2018: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

Top Bank Stocks To Watch For 2018: Panasonic Corporation (PCRFY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Clean Technica reported on September 1 that “Sony is entering the EV battery manufacturing industry”. And “considering that electric vehicle batteries are going to be the main supply bottleneck for the upcoming auto market’s embrace of EVs, the entry of Sony into the field is very notable. Most of the other manufacturers (Panasonic (OTCPK:PCRFY), LG Chem (OTC:LGCLF), etc.) already have more or less all of their production capacity locked up for the coming years – meaning there’s not much left for the auto manufacturers that are running behind, thereby limiting potential EV sales for the firms in question. Sony’s (NYSE:SNE) entry into the field should open things up a bit more”. Certainly a good move by Sony and helpful for the EV companies that will find themselves in need of batteries, and limited availability, should EVs reach 10% by 2020.

  • [By Ben Levisohn]

    During the early stages of a new innovation, interdependent architectures and integrated companies best optimize performance and functionality. This trend has played out in computing and handsets, and we see the same trend playing out in EVs. We find Tesla and BYD1 , by far, the most vertically integrated players in EVs, with huge scale advantages. In addition, LG Chem, Panasonic (PCRFY), Samsung SDI, BYD, and CATL are clear scale leaders in batteries (CATL is not publicly traded. All but Samsung SDI and BYD are not covered by Bernstein.).

  • [By SEEKINGALPHA.COM]

    SMMYY is a subsidiary of the Sumitomo Group. SMMYY is a major smelter and refiner of copper, nickel and gold in Japan, and has a 27.5% stake in the Ambatovy Nickel Project in Madagascar, along with Sherritt International and Korea Resources Corp. Feedstock for the refinery is nickel cobalt mixed sulphide from its Taganito and Coral Bay mines in the Philippines (noting the Philippines is a risky supply source at this time). Sumitomo supply Panasonic (OTCPK:PCRFY) who supply Tesla (NASDAQ:TSLA); however, this can change. Generally, I like the stock; however, at this time, valuation looks full, trading on a 2017 PE of 32.8, and 2018 PE of 14.8. Good to buy after a pullback if that occurs.

  • [By SEEKINGALPHA.COM]

    A Unilever vs. Panasonic (OTCPK:PCRFY) showdown seems to be something out of an alternative, weird universe. But that’s exactly what has been happening in the Asia-Pacific region, where Unilever is now a major seller of air and water purification devices. The acquisitions of Qinyuan and Pureit water purifiers, as well as the acquisition of Sweden-based Blueair in 2016, reflects Unilever’s latest growth strategy of reducing exposure to low-growth brands in favor of greater investments in higher-growth products with strong social and environmental credentials.

Top Bank Stocks To Watch For 2018: Intercept Pharmaceuticals, Inc.(ICPT)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:

  • [By Paul Ausick]

    Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) dropped more than 17% Friday to post a new 52-week low of $60.97 after closing Thursday at $73.70. The 52-week high is $172.75. Volume of more than 10 million shares traded was about 12 times the daily average. The FDA on Thursday issued a warning letter on the company’s liver disease treatment.

Top Bank Stocks To Watch For 2018: Realogy Holdings Corp.(RLGY)

Advisors’ Opinion:

  • [By Lisa Abramowicz]

    Drugstore chain Rite Aid Corp. (RAD) and residential property firm Realogy Corp. (RLGY) are two of the 283 junk-rated borrowers identified in March 2009 by Moodys Investors Service as being at the highest risk of default that have since sold bonds.

  • [By Monica Wolfe]

    Realogy Holdings (RLGY)

    Paulsons third largest holding goes to Realogy Holdings. The guru holds on to 12,957,700 shares, representing 4.4% of his total portfolio and 8.87% of the companys shares outstanding.

  • [By Chad Tracy]

    Investments in Claire's retail stores, Realogy Holdings (NYSE: RLGY), and Harrah's Entertainment all came under pressure as the global credit crisis hit. Apollo was forced to shut off cash interest payments to investors and to issue more debt.  

Top Bank Stocks To Watch For 2018: Neptune Technologies & Bioresources Inc(NEPT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Neptune Technologies & Bioressources (NASDAQ: NEPT) is projected to post a quarterly loss at $0.01 per share on revenue of $9.70 million.

    Apigee Corp (NASDAQ: APIC) is expected to post a quarterly loss at $0.27 per share on revenue of $23.17 million.

  • [By Jim Robertson]

    Yesterday, our Under the Radar Movers newsletter suggested small cap functional ingredient stock Neptune Technologies & Bioressources (NASDAQ: NEPT) as a long/bullish trade:

Top Bank Stocks To Watch For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

Leave a Reply

Your email address will not be published. Required fields are marked *